Clear corneal phaco reduces IOP

Article

Clear corneal phacoemulsification induces a small reduction in intraocular pressure (IOP), according to the results of a study published in the December 2006 issue of the Journal of Glaucoma.

Clear corneal phacoemulsification induces a small reduction in intraocular pressure (IOP), according to the results of a study published in the December 2006 issue of the Journal of Glaucoma.

Bradford Shingleton, MD and co-workers at Ophthalmic Consultants of Boston, USA, conducted a retrospective study of the long-term changes in IOP after clear corneal phacoemulsification. They examined 55 eyes of 48 patients with open-angle glaucoma, 44 eyes of 41 patients with suspected glaucoma and a control group of 59 eyes of 59 patients with no glaucoma. All patients completed a follow-up period of at least three years.

At three years follow-up, a mean IOP decrease of 1.4 mmHg was recorded among patients with glaucoma and glaucoma suspects. In the control group, there was a mean decrease of 1.7 mmHg. Most patients achieved IOPs equal or lower to their preoperative IOP without increasing the number of medications used.

At final follow-up, IOP remained significantly lower in all three groups. At a mean of five years, IOP had decreased by an average of 1.8 mmHg for glaucoma patients, 1.3 mmHg for glaucoma suspects and by 1.5 mmHg in the control group. Additionally, 76% of glaucoma patients, 79% of glaucoma suspects and 83% of the control group maintained IOPs of less or equal to the baseline without increasing the number of glaucoma medications.

The authors concluded that clear corneal phacoemulsification can induce a small but significant reduction in IOP that is sustained up to five years postoperatively.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.